Physician profile
Mark A Robinson
NPI 1821236597
$2,184.58
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $312 · 2021: $386 · 2022: $555 · 2023: $432 · 2024: $37.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $351.64 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $324.58 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $262.42 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $119.11 | 2019-2022 | |
| Abbott Laboratories | $113.53 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $113.33 | 2019-2020 | |
| Abbvie INC. | $107.00 | 2019-2023 | Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $96.35 | 2019-2022 | |
| Lilly USA, LLC | $93.27 | 2019-2021 | |
| Amarin Pharma, INC. | $88.61 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.84 | 2019-2023 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.97 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $51.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.11 | 2019-2020 | |
| Exact Sciences Corporation | $42.71 | 2023 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.29 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.69 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $26.19 | 2023 | Auvelity |
| Sanofi Pasteur INC. | $20.56 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $17.85 | 2021 | |
| Pulmonx Corporation | $16.87 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2021 | |
| Lucid Diagnostics INC. | $12.84 | 2022 | |
| Esperion Therapeutics, INC. | $12.02 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.